Incyte partners with Genmab on metastatic colorectal cancer trial
INCY•Incyte and Genmab entered a clinical trial collaboration for KRAS G12D-mutated metastatic colorectal cancer, testing INCB161734 with petosemtamab and standard chemotherapy as a first-line treatment.
1. Trial collaboration
The Phase 1/2 trial will evaluate INCB161734 with petosemtamab and standard chemotherapy as a first-line treatment. Genmab will conduct the study, while Incyte will co-fund it and supply INCB161734.
